MYND Life Sciences Inc.
MYND
CNSX
| 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | 07/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 3.30% | -7.96% | 0.51% | 41.95% | 81.27% |
| Gross Profit | -3.30% | 7.96% | -0.51% | -41.95% | -41.61% |
| SG&A Expenses | -49.01% | -52.35% | -30.38% | -29.65% | -51.19% |
| Depreciation & Amortization | -92.37% | -92.48% | -79.68% | -66.52% | -61.75% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -34.78% | -46.59% | -42.59% | -43.44% | -54.20% |
| Operating Income | 34.78% | 46.59% | 42.59% | 43.44% | 54.72% |
| Income Before Tax | 79.94% | 76.93% | 68.30% | 60.85% | 62.87% |
| Income Tax Expenses | -- | -- | -- | -- | 22.48% |
| Earnings from Continuing Operations | 78.90% | 75.88% | 67.00% | 59.48% | 63.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 78.90% | 75.88% | 67.00% | 59.48% | 63.84% |
| EBIT | 34.78% | 46.59% | 42.59% | 43.44% | 54.72% |
| EBITDA | 34.76% | 46.62% | 42.61% | 43.47% | 54.66% |
| EPS Basic | 78.38% | 75.70% | 66.67% | 59.04% | 64.33% |
| Normalized Basic EPS | 44.40% | 45.72% | 39.52% | 36.15% | 62.67% |
| EPS Diluted | 78.38% | 75.70% | 66.67% | 59.04% | 64.33% |
| Normalized Diluted EPS | 44.40% | 45.72% | 39.52% | 36.15% | 62.67% |
| Average Basic Shares Outstanding | 0.44% | 1.18% | 1.18% | 0.63% | 1.24% |
| Average Diluted Shares Outstanding | 0.44% | 1.18% | 1.18% | 0.63% | 1.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |